Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 40 articles:
HTML format
Text format



Single Articles


    April 2017
  1. HAYDU LE, Scolyer RA, Lo S, Quinn MJ, et al
    Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    J Clin Oncol. 2017 Apr 4:JCO2016719393. doi: 10.1200/JCO.2016.71.9393.
    PubMed     Text format     Abstract available


    February 2017
  2. KOHN CG, Zeichner SB, Chen Q, Montero AJ, et al
    Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol. 2017 Feb 21:JCO2016696336. doi: 10.1200/JCO.2016.69.6336.
    PubMed     Text format     Abstract available


    January 2017
  3. AGARWALA SS, Lee SJ, Yip W, Rao UN, et al
    Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Rese
    J Clin Oncol. 2017 Jan 30:JCO2016702951. doi: 10.1200/JCO.2016.70.2951.
    PubMed     Text format     Abstract available


  4. D'ANGELO SP, Larkin J, Sosman JA, Lebbe C, et al
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    J Clin Oncol. 2017;35:226-235.
    PubMed     Text format     Abstract available


  5. WATTS CG, Cust AE, Menzies SW, Mann GJ, et al
    Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
    J Clin Oncol. 2017;35:63-71.
    PubMed     Text format     Abstract available


    December 2016
  6. POWELL CA
    Pulmonary Infiltrates in a Patient With Advanced Melanoma.
    J Clin Oncol. 2016 Dec 28:JCO2016699793.
    PubMed     Text format     Abstract available


  7. DIENG M, Butow PN, Costa DS, Morton RL, et al
    Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2016;34:4405-4414.
    PubMed     Text format     Abstract available


  8. DAUD AI, Wolchok JD, Robert C, Hwu WJ, et al
    Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    J Clin Oncol. 2016;34:4102-4109.
    PubMed     Text format     Abstract available


    November 2016
  9. NIJSTEN T
    Sunscreen Use in the Prevention of Melanoma: Common Sense Rules.
    J Clin Oncol. 2016;34:3956-3958.
    PubMed     Text format    


  10. WEBER JS, Hodi FS, Wolchok JD, Topalian SL, et al
    Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2016 Nov 14:JCO2015661389.
    PubMed     Text format     Abstract available


    September 2016
  11. GHIASVAND R, Weiderpass E, Green AC, Lund E, et al
    Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Sep 12. pii: JCO675934.
    PubMed     Text format     Abstract available


    June 2016
  12. PUZANOV I, Milhem MM, Minor D, Hamid O, et al
    Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    J Clin Oncol. 2016 Jun 13. pii: JCO671529.
    PubMed     Text format     Abstract available


    May 2016
  13. GOFF SL, Dudley ME, Citrin DE, Somerville RP, et al
    Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
    J Clin Oncol. 2016 May 23. pii: JCO667220.
    PubMed     Text format     Abstract available


    April 2016
  14. SONDAK VK, McIver B, Kanetsky PA
    Vitamin D and Melanoma: What Do We Tell Our Patients?
    J Clin Oncol. 2016 Apr 4. pii: JCO665240.
    PubMed     Text format    


    March 2016
  15. FANG S, Sui D, Wang Y, Liu H, et al
    Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.
    J Clin Oncol. 2016 Mar 21. pii: JCO641357.
    PubMed     Text format     Abstract available


  16. INDINI A, Di Nicola M, Del Vecchio M, De Braud F, et al
    Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
    J Clin Oncol. 2016;34:1017-8.
    PubMed     Text format    


  17. HORVAT TZ, Adel NG, Dang TO, Momtaz P, et al
    Reply to A. Indini et al.
    J Clin Oncol. 2016;34:1018-9.
    PubMed     Text format    


  18. HODI FS, Hwu WJ, Kefford R, Weber JS, et al
    Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
    J Clin Oncol. 2016 Mar 7. pii: JCO640391.
    PubMed     Text format     Abstract available


    February 2016
  19. WILGENHOF S, Corthals J, Heirman C, van Baren N, et al
    Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    J Clin Oncol. 2016 Feb 29. pii: JCO634121.
    PubMed     Text format     Abstract available


  20. BERWICK M
    Reply to S. Lehrer et al and J.C. Dowdy and R.M. Sayre.
    J Clin Oncol. 2016;34:638-9.
    PubMed     Text format    


  21. WU S, Cho E, Qureshi AA
    Reply to S. Lehrer et al and J.C. Dowdy and R.M. Sayre.
    J Clin Oncol. 2016;34:637-8.
    PubMed     Text format    


  22. MCMASTERS KM, Egger ME, Edwards MJ, Ross MI, et al
    Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biop
    J Clin Oncol. 2016 Feb 8. pii: JCO633776.
    PubMed     Text format     Abstract available


    January 2016
  23. LONG GV, Weber JS, Infante JR, Kim KB, et al
    Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2016 Jan 25. pii: JCO629345.
    PubMed     Text format     Abstract available


  24. PULVIRENTI T, Hong A, Clements A, Forstner D, et al
    Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.
    J Clin Oncol. 2016;34:e17-20.
    PubMed     Text format    


  25. BULLOCH KJ, Narayan D, Ariyan S, Gould Rothberg BE, et al
    Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  26. DOWDY JC, Sayre RM
    Melanoma Risk From Dietary Furocoumarins: How Much More Evidence Is Required?
    J Clin Oncol. 2016 Jan 4. pii: JCOJCO638643.
    PubMed     Text format    


  27. LEHRER S, Green S, Rosenzweig KE
    Melanoma Risk and Citrus Consumption.
    J Clin Oncol. 2016 Jan 4. pii: JCO638254.
    PubMed     Text format    


    November 2015
  28. FANG S, Wang Y, Amos CI, Lee JE, et al
    Reply to Z. Li et al.
    J Clin Oncol. 2015;33:3674-5.
    PubMed     Text format    


  29. CHIOU VL, Burotto M
    Pseudoprogression and Immune-Related Response in Solid Tumors.
    J Clin Oncol. 2015;33:3541-3.
    PubMed     Text format    


    October 2015
  30. MOHR P, Hauschild A, Trefzer U, Enk A, et al
    Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    J Clin Oncol. 2015 Oct 26. pii: JCO.2014.59.6932.
    PubMed     Text format     Abstract available


    September 2015
  31. LAWSON DH, Lee S, Zhao F, Tarhini AA, et al
    Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After C
    J Clin Oncol. 2015 Sep 8. pii: JCO.2015.62.0500.
    PubMed     Text format     Abstract available


    August 2015
  32. HORVAT TZ, Adel NG, Dang TO, Momtaz P, et al
    Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    J Clin Oncol. 2015 Aug 17. pii: JCO.2015.60.8448.
    PubMed     Text format     Abstract available


  33. LI Z, Feng J, Sun X
    Is C-Reactive Protein a Specific Marker in Melanoma?
    J Clin Oncol. 2015 Aug 3. pii: JCO.2015.62.2696.
    PubMed     Text format    


  34. LAM CJ, Curtis RE, Dores GM, Engels EA, et al
    Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
    J Clin Oncol. 2015 Aug 3. pii: JCO.2014.60.2094.
    PubMed     Text format     Abstract available


    July 2015
  35. MEVES A, Nikolova E, Heim JB, Squirewell EJ, et al
    Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
    J Clin Oncol. 2015 Jul 6. pii: JCO.2014.60.7002.
    PubMed     Text format     Abstract available


    June 2015
  36. BERWICK M
    Dietary Advice for Melanoma: Not Ready for Prime Time.
    J Clin Oncol. 2015 Jun 29. pii: JCO.2015.61.8116.
    PubMed     Text format    


  37. WU S, Han J, Feskanich D, Cho E, et al
    Citrus Consumption and Risk of Cutaneous Malignant Melanoma.
    J Clin Oncol. 2015 Jun 29. pii: JCO.2014.57.4111.
    PubMed     Text format     Abstract available


    May 2015
  38. ANDTBACKA RH, Kaufman HL, Collichio F, Amatruda T, et al
    Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    J Clin Oncol. 2015 May 26. pii: JCO.2014.58.3377.
    PubMed     Text format     Abstract available


  39. GIBNEY GT, Atkins MB
    Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2015 May 11. pii: JCO.2014.60.1807.
    PubMed     Text format    


    March 2015
  40. DAUD AI, Ashworth MT, Strosberg J, Goldman JW, et al
    Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
    J Clin Oncol. 2015;33:1060-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: